Otonomy Seen Rallying Up To 95% On Positive Meniere's Disease Data
August 15, 2017 at 12:40 PM EDT
JPMorgan this morning upgraded Otonomy (OTIC) to Overweight from Neutral, saying that the stock could rise up to 95% if the results of an upcoming trial of its Otividex drug are positive.
